AuntMinnieEurope.com staff writers

Molecular Imaging

Clarity highlights Cu-64 PSMA-PET/CT study results

The study compares Clarity's copper-64 (Cu-64) SAR-bisPSMA PET/CT agent with standard gallium-68 PSMA-11 PET/CT.

March 18, 2026

Nvision, Aarhus secure €5.4M grant for hyperpolarized MRI project

Nvision Imaging Technologies and Aarhus University have received a €5.4 million grant for their hyperpolarized MRI liver cancer diagnostics project.

March 16, 2026

Liver Digital Tablet 400

ECR 2026 draws record number of participants to Vienna

ECR 2026 drew a record number of participants, including a 9% increase from ECR 2025.

March 12, 2026

Esaote unveils new IR ultrasound systems, MRI AI at ECR 2026

Esaote has launched two new ultrasound systems for interventional radiologists (IR).

March 6, 2026

Esaote's MyLab385 GTS

Carpl.ai partners with Medica for NHS Trust teleradiology project

Carpl.ai notes a "significant shift" in how AI is validated and embedded into live clinical workflows.

March 6, 2026

Business Handshake Intelligence Sm

Sectra to acquire AI radiology developer Oxipit

Sectra will acquire Oxipit, a developer of AI tools for x-ray and CT analyses.

March 5, 2026

Sectra Rsna 2019 400

Harrison.ai expands Open Platform with 4 new AI partners

Harrison.ai will add the AI tools of AIRAmed, Koios Medical, Lunit, and Nanox AI to its Open Platform ecosystem.

March 4, 2026

Business Partner Handshake Intelligence

Raydiax secures €7.5M toward interventional oncology system

Venture capital funding and a European Innovation Council Accelerator grant will support the market launch.

March 4, 2026

German Flag Button Thumbnail

German Medical Institute selects Oxipit for chest x-ray AI

Following a clinical evaluation of vendors and products, the German Medical Institute in Limassol, Cyprus, has chosen Oxipit for chest x-ray AI.

March 3, 2026

Artificial Intelligence Lung Color 400

Bracco launches AiMIFY in EU, announces Avicenna.AI collaboration

Bracco Diagnostics Inc.

Bracco has announced the EU launch of AiMIFY and a strategic partnership with Avicenna.AI on contrast-enhanced CT.

March 3, 2026

Bracco2 Rsna 2018 400

Page 5 of 959

Doctors Residents Student Education 400

EBR accepts registrations for EDiR, launches EDiR Academy

Three months after thermal ablation, contrast-enhanced CT (A, B) shows post-treatment changes without clear local progression, while FDG-PET/CECT (C–F) reveals focal uptake suspicious for recurrence.

FDG-PET/CT sharpens surveillance after colorectal liver metastasis treatment

Pexels Thirdman 8940356 (1)

Scottish team designs 10-year sustainability model for preclinical imaging

Overview of the hallmarks of cancer and the imaging modalitites that are being used to assess them.

ESMI review maps cancer biology ahead of TOPIM 2026

Forum

Behind the Editors' desk: How AI Is reshaping scientific publishing

AI may provide early breast cancer alerts from mammograms

By Amerigo Allegretto

Commercial AI systems could provide early alerts for breast cancer by picking out early signs of the disease on mammograms.

June 9, 2026

Screening mammograms and AI score changes are depicted over time in two individuals with screen-detected cancer. Full-field digital mammograms show craniocaudal (top) and mediolateral (bottom) views of the left and right breast. The description below each mammogram indicates whether AI scores from three AI-based computer-aided detection systems (AI-1, AI-2, and AI-3) were above or below the 90th percentile. (A) Mammograms from three screening time points (in 2009, 2011, and 2014) in an individual who was diagnosed in February 2014 (at age 73 years) with a left-sided 25-mm grade 2 invasive breast carcinoma, no special type (arrow). Mammographic breast density was classified as BI-RADS B on all three mammograms. (B) Mammograms from four screening time points (in 2009, 2011, 2013, and 2015) in an individual who was diagnosed in October 2015 (at age 65 years) with a left-sided 45-mm grade 2 lobular carcinoma (arrow). Mammographic breast density was classified as BI-RADS C on all four mammograms. Screen-detected cancers were defined as those diagnosed within 90 days for individuals who were recalled at screening (*).

Tattoo pigments can have significant impact on imaging

Tattoos can appear as shadows or artifacts on an x-ray, causing confusion during interpretation. Research presented at the U.K. Imaging and Oncology congress has provided new data on which tattoo inks have the greatest impact.

June 8, 2026

2026 06 08 Tattoos Homepage Image

SERAM 2026: Biparametric MRI cuts time and costs in prostate cancer imaging

By Claudia Tschabuschnig

A study presented at SERAM 2026 suggests that biparametric MRI (bpMRI) can reduce exam time and costs in patients with clinically significant prostate cancer.

June 8, 2026

Biparametric prostate MRI identified clinically significant Gleason 3+4 prostate cancer using T2-weighted imaging, diffusion-weighted imaging, and ADC mapping alone.

SERAM 2026: AI chest triage cuts referrals without raising CT use

By Claudia Tschabuschnig

A real-world implementation study from a Spanish regional hospital suggests that AI-assisted chest radiograph triage may reduce specialist referrals without driving additional CT imaging.

June 4, 2026

An AI system highlights multiple abnormalities on a chest radiograph, including a pulmonary nodule (nódulo pulmonar), pleural effusion (derrame pleural), and alveolar syndrome/consolidation (síndrome alveolar).

AI detects lung cancer nodules well but shows low specificity

By Kate Madden Yee

The finding suggests the models offer “a potential role as adjunctive tools for ruling out malignancy” rather than classifying it.

June 4, 2026

Am 2020 06 26 16 29 2945 Cancer Lung 400

Image-guided focal laser ablation effective for prostate cancer

By Amerigo Allegretto

MRI-directed, ultrasound-guided TPLA may be a promising technique to treat prostate cancer while avoiding radical therapies.

June 3, 2026

Preablation, postablation, and recurrence multiparametric MRI scans depict a 63-year-old man treated with transperineal focal laser ablation (TPLA) for localized prostate cancer. Clinical parameters included an initial prostate-specific antigen (PSA) level of 7.2 ng/mL, a Prostate Imaging Reporting and Data System (PI-RADS) grade 4 lesion (red circles) in the right apical peripheral zone, and a maximum tumor length of 5 mm. MRI-guided targeted biopsy confirmed a Gleason score 3+4 prostate cancer tumor. (A) Pre-ablation axial T2-weighted MRI scan and apparent diffusion coefficient (ADC) image shows the apical PI-RADS 4 lesion (circles). (B) Six-month post-ablation axial T2-weighted MRI scan and ADC image show cystic necrosis (arrows). There was no evidence of recurrence; the PSA level was 1.5 ng/mL. (C) One-year after ablation, the patient’s PSA level had increased to 4.3 ng/mL. Axial T2-weighted MRI scan and the ADC image shows a recurrent lesion (blue circles) in the right apical peripheral zone adjacent to the ablation scar. Targeted biopsy confirmed Gleason score 3+4 prostate cancer, which was classified as in-field recurrence of clinically significant prostate cancer and subsequently re-treated with TPLA. In summary, serial multiplanar MRI demonstrates treatment response after TPLA with post-ablation necrosis, followed by MRI-detected IFR confirmed with biopsy at 12-month follow-up. Multiparametric MRI was performed with a 3.0-T MRI scanner (Skyra; Siemens Healthineers) using T2-weighted, diffusion-weighted, and ADC sequences, with gadobenate dimeglumine contrast material administration (Bracco Diagnostics).

Spain's radiology society warns CT renewal still far short despite new procurement drive

By Claudia Tschabuschnig

SERAM's new equipment guide says Spain needs around 80 CT scanners a year. A new government purchasing framework covers 62 over two years, and the MRI and vascular equivalents are still missing.

June 3, 2026

Gioele Gatto/Pexels

AI can mislead radiologists -- and make the error more persuasive

By Claudia Tschabuschnig

A study from Milan puts hard numbers on how often radiologists follow a wrong AI recommendation and whether explainable AI can help.

June 2, 2026

Grad-CAM heatmaps showing the AI model's areas of attention overlaid on standard mammography views, as displayed to radiologists during the XAI-assisted reading sessions.

SERAM 2026: AI-assisted triage in deep neck infections

By Claudia Tschabuschnig

AI models trained on CT and laboratory data showed promise for predicting ICU admission, surgery and tracheostomy in patients with deep neck infections.

June 1, 2026

Valencia became the center of Spanish radiology from 20–23 May as the city hosted SERAM 2026, one of the country's largest medical imaging meetings.

SNMMI: SPECT/CT tracer shows promise in interstitial lung disease

Differentiating between fibrotic scarring and inflammation stages of disease is critical so that physicians can determine what treatment is best for the patient.

May 31, 2026

Sample images from each participant group: A: CT only; B: fused Tc-99m maraciclatide SPECT/CT.

SNMMI: Machine-learning model predicts RPT dose

Dosimetry plays a central role in optimizing lutetium-177 (Lu-177) PSMA therapy, yet calculating it currently depends on post-therapy imaging.

May 30, 2026

Eye movement abnormalities flag brain health risk in ex-racing drivers

By Kate Madden Yee

A case series of 12 male retired professional motorsport drivers showed a high prevalence of mild neurological abnormalities.

May 29, 2026

Page 5 of 88